Changemakers on a mission

Researchers have completed the PROSPER trial, a clinical study examining whether two commonly available medications—propranolol and etodolac—could improve outcomes when administered around the time of pancreatic cancer surgery.

The European Medicines Agency (EMA) has released findings from its Pilot Program on drug repurposing, marking a significant step toward establishing new regulatory pathways that could transform how existing medicines are developed for new therapeutic uses across Europe.

New research published in the journal Cancer Research provides evidence that adaptive therapy represents a promising strategy to address one of oncology's challenges: drug resistance. Anticancer Fund is supporting clinical trials that explore this treatment approach, which offers a different perspective on how to treat cancer.

The Anticancer Fund is now part of FORCE, a major European initiative supporting research on rare and hard-to-treat cancers. Alongside 13 non-profit partners from 11 countries, we’re working to bring better, evidence-based treatments to patients who urgently need them.